The aim of the project is to optimise and preclinical profiling of selected compounds with unique biological activity with the potential to demonstrate therapeutic efficacy in minimal undesirable side effects in the field of oncology and cardiology. The project will include the preparation of a wide set of compounds and thorough testing of biological and especially pharmacological properties, including in vivo studies. The intellectual property generated will be treated consistently. Results (TRL3) will be completed with application companies. a.